Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.

Oncotarget · 2015 · PMC4484414 · PMID 25926554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

However, no significant difference was apparent between Ad. vec -, Ad.tCCN1-CRCA - or Ad.tCCN1- CTV -infected RWPE-1 cells at lower MOI (100 vp/cell), supporting the cancer-selective properties of these conditionally oncolytic viruses.

also in 455 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.